Incidence of Adverse Drug Events and Medication Errors in Japan: the JADE Study
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The epidemiology of adverse drug events (ADEs) and medication errors has received little evaluation outside the U.S. and Europe, and extrapolating from these data might not be valid, especially regarding selecting and prioritizing solutions.
To assess the incidence and preventability of ADEs and medication errors in Japan.
The Japan Adverse Drug Events (JADE) study was a prospective cohort study.
A cohort of 3,459 adults admitted to a stratified random sample of seven medical and eight surgical wards and three intensive care units in three tertiary care hospitals over 6 months.
We measured ADE and medication error rates from daily reviews of charts, laboratories, incident reports, and prescription queries by on-site reviewers; presence of a signal was considered an incident. Two independent physicians reviewed incidents to determine whether they were ADEs or medication errors and to assess severity and preventability.
We identified 1,010 ADEs and 514 medication errors (incidence: 17.0 and 8.7 per 1,000 patient-days, respectively) during the study period. Among ADEs, 1.6%, 4.9% and 33% were fatal, life-threatening and serious, respectively. Among ADEs, 14% were preventable. The rate per admission was 29 per 100 admissions, higher than in U.S. studies because associated with of the long length of hospital stay in Japan (mean, 17 days).
The epidemiology and nature of ADEs and medication errors in Japan were similar to other countries, although more frequent per admission. Solutions that worked in these countries might thus improve medication safety in Japan, as could shortening hospital length of stay.
- Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13(4):306–314. CrossRef
- Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard medical practice study II. N Engl J Med. 1991;324(6):377–384. CrossRef
- Jha AK, Prasopa-Plaizier N, Larizgoitia I, Bates DW. Patient safety research: an overview of the global evidence. Qual Saf Health Care. 2010;19(1):42–47. CrossRef
- Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. Jama. 1995;274(1):29–34.
- Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–1564. CrossRef
- Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. Jama. 2001;285(16):2114–2120. CrossRef
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200–1205. CrossRef
- Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. Jama. 1997;277(4):307–311. CrossRef
- Ogilvie RI, Ruedy J. Adverse drug reactions during hospitalization. Can Med Assoc J. 1967;97(24):1450–1457.
- Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1969;1(5643):531–536. CrossRef
- Smidt NA, McQueen EG. Adverse drug reactions in a general hospital. N Z Med J. 1973;78(494):39.
- Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117(7):459–468. CrossRef
- Bates DW, Larizgoitia I, Prasopa-Plaizier N, Jha AK. Global priorities for patient safety research. BMJ. 2009;338:b1775. CrossRef
- Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J Gen Intern Med. 2010;25(1):31–38. CrossRef
- Anbacken O. Japanese hospitals–culture and competition: a study of ten hospitals. Int J Health Plann Manage. 1994;9(1):87–101. CrossRef
- Muramatsu N, Liang J. Hospital length of stay in the United States and Japan: a case study of myocardial infarction patients. Int J Health Serv. 1999;29(1):189–209.
- Nomura H, Nakayama T. The Japanese healthcare system. BMJ. 2005;331(7518):648–649. CrossRef
- Bates DW. Using information technology to reduce rates of medication errors in hospitals. BMJ. 2000;320(7237):788–791. CrossRef
- Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348(25):2526–2534. CrossRef
- Mycyk MB, McDaniel MR, Fotis MA, Regalado J. Hospitalwide adverse drug events before and after limiting weekly work hours of medical residents to 80. Am J Health Syst Pharm. 2005;62(15):1592–1595. CrossRef
- Incidence of Adverse Drug Events and Medication Errors in Japan: the JADE Study
Journal of General Internal Medicine
Volume 26, Issue 2 , pp 148-153
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- adverse drug events
- medication errors
- patient safety
- Industry Sectors
- Author Affiliations
- 1. Center for Medical Education, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, 606-8501, Japan
- 2. Department of General Medicine, Yamaguchi University Hospital, Ube, Japan
- 3. Rakuwakai Otowa Hospital, Kyoto, Japan
- 4. Aso Iizuka Hospital, Iizuka, Japan
- 5. St. Luke’s International Hospital, Tokyo, Japan
- 6. Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA